Patients across Canada are anxiously awaiting approval of lower-cost generic versions of Ozempic, as high prices continue to put the drug out of reach for many without coverage.
Ozempic, widely used for diabetes and weight management, can cost hundreds of dollars per month, leaving seniors and uninsured patients struggling to afford treatment. Public drug plans, including those guided by Health Canada approvals, typically cover the medication only for diabetes — not for weight loss.
Experts say up to nine generic versions of semaglutide are currently under review in Canada, raising hopes for significant price reductions. Depending on competition, costs could drop to as low as 35 per cent of the brand-name price once multiple generics enter the market.
Healthcare professionals note that affordability remains the biggest barrier, especially for patients managing obesity without insurance. At the same time, rising demand has made Ozempic one of the largest drivers of public drug spending nationwide.
While Canada could soon approve its first generic semaglutide products, patients are still waiting — hoping cheaper options will arrive soon enough to improve access and long-term health outcomes.